Syncromune®, Inc. Presents Phase 1 Data Highlighting Resolution of Bone Metastases in Metastatic Prostate Cancer Patients at Society of Urological Oncology 26th Annual Meeting

Posted December 4, 2025

Syncromune®, Inc. to Present Phase 1 Data Highlighting Resolution of Bone Metastases in Metastatic Prostate Cancer Patients at the Society of Urological Oncology 26th Annual Meeting

Posted November 20, 2025

Syncromune® Appoints Industry Veteran Kerri-Ann Millar as Chief Financial Officer to Advance Corporate Growth Initiatives and Clinical Development Program

Posted June 16, 2025

Syncromune® Inc. Presents Positive Results from SYNC-T™ Therapy SV-102 Phase 1 Metastatic Prostate Cancer Trial at ASCO 2025

Posted June 2, 2025

Syncromune® Announces First Patient Dosed in LEGION-100 Phase 2a Trial of SYNC-T™ Therapy SV-102 for Patients with Metastatic Castration-Resistant Prostate Cancer

Posted May 30, 2025

Syncromune® Inc. Announces Publication of Abstract on SYNC-T™ Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual Meeting

Posted May 23, 2025

Syncromune® Inc. to Present Clinical Data from SYNC-T Therapy SV-102 Phase 1 Trial at the American Society for Clinical Oncology Annual Meeting 2025

Posted April 25, 2025

Syncromune Appoints Zhihong Li, Ph.D., as Chief Regulatory Affairs Officer to Lead Global Regulatory Strategy for Novel Oncology Immunotherapies

Posted March 25, 2025